Guided Therapeutics (GTHP) Net Income (2010 - 2025)

Guided Therapeutics has disclosed Net Income across 16 years of filings, most recently posting -$1.2 million for Q4 2025.

• Net Income for Q4 2025 came in at -$1.2 million, down 86.81% year-over-year; the trailing twelve-month figure through Dec 2025 was -$3.2 million (down 32.31% YoY), and the FY2025 annual result was -$3.2 million, down 32.23% from the prior year.
• Net Income came in at -$1.2 million for Q4 2025 at Guided Therapeutics, down from -$742000.0 in the prior quarter.
• In the past five years, Net Income ranged from a high of $68000.0 in Q3 2021 to a low of -$1.8 million in Q4 2022.
• The 5-year median for Net Income is -$693000.0 (2023), against an average of -$768650.0.
• Across the five-year window, Net Income surged 84.68% in 2021 and slumped 1720.59% in 2022, its largest moves.
• Guided Therapeutics' Net Income stood at -$444000.0 in 2021, then slumped by 306.98% to -$1.8 million in 2022, then surged by 78.64% to -$386000.0 in 2023, then slumped by 68.91% to -$652000.0 in 2024, then plunged by 86.81% to -$1.2 million in 2025.
• The last three Net Income figures came in at -$1.2 million (Q4 2025), -$742000.0 (Q3 2025), and -$811000.0 (Q2 2025), per Business Quant data.